
DYAI Stock Forecast & Price Target
DYAI Analyst Ratings
Bulls say
Dyadic International Inc. has reported substantial revenue growth in its 3Q24 financial results, attributed to increased interest in its gene expression platform, C1, and the proprietary Dapibus technology, both of which have gained traction in licensing agreements. The company recognized $1 million in licensing revenue from a deal with PHB and an additional success fee of $425,000 from Inzymes ApS for developing non-animal dairy enzymes. This positive momentum reflects Dyadic's strategic positioning to capitalize on the rising demand for cost-effective production of biologic products, such as therapeutics and vaccines, enhancing its prospects for future growth.
Bears say
Dyadic International Inc. reported a net loss of $0.2 million in the third quarter of 2024, indicating ongoing financial struggles as the company continues to invest in its biotechnology platform. The company faces significant risks, including the possibility of unsuccessful clinical trials and the challenges associated with regulatory requirements for further studies, which could hinder its commercialization efforts. Additionally, there are concerns regarding the company’s ability to differentiate its products competitively, potential issues with intellectual property rights, and the risk of needing to secure additional funding under adverse market conditions.
This aggregate rating is based on analysts' research of Dyadic International Inc., DE and is not a guaranteed prediction by Public.com or investment advice.
DYAI Analyst Forecast & Price Prediction
Start investing in DYAI
Order type
Buy in
Order amount
Est. shares
0 shares